Harbour BioMed s pleased to announce the appointment of Mr. Weihao Xu as Chief Strategy Officer (CSO), who will base in San Francisco. Mr. Xu will be the Global Head of Business Development and Corporate Development, responsible for developing and executing strategy for partnership and corporate investment, building innovation capabilities as well as an overall business ecosystem to drive growth. He will also be involved in corporate and product portfolio strategy, and investor relations activities in the US.
Latest Fintech Insights:Â Kueski, One of the Largest BNPL Providers in Latin America, has Closed Over US$200M in Financing, Led by StepStone Group and Victory Park Capital
By joining HBM, Mr Xu will be bringing with him more than 15 years of extensive experience in global capital markets, equity investment and financial management. Before HBM, Mr. Xu served as Chief Finance Officer at Alphamab Oncology, CASI Pharmaceuticals, and 111 Inc. Prior to that, he was active in the investment industry, working as the Portfolio Manager for Matthews Asia and several other international investment institutions, where he was responsible for global equity investments.
Browse The Complete News About Fintech :Â Paysafe: US In-store SMBs Embrace Payments Technology Alongside Cash Acceptance
Mr. Xu holds a master’s degree in Accounting from Columbia Business School. He also completed a certified program in High Impact Cancer Research from Harvard Medical School.
Read More About Fintech News :Â JLL Arranges $690M Financing for 44-Property Industrial Portfolio
[To share your insights with us, please write to sghosh@martechseries.com]
